What the FDA's March 2024 Cybersecurity in Medical Devices Quality System Regulation Proposal Means for Device Manufacturers

The FDA published a proposed rule in March 2024 that would amend the Quality System Regulation (21 CFR Part 820) to incorporate cybersecurity requirements directly into design controls, risk management, and post-market monitoring for medical devices. The proposal would make cybersecurity a mandatory design input rather than a voluntary consideration, with documentation and lifecycle management obligations enforceable under the same framework that governs device safety and effectiveness.

I cannot locate the specific March 2024 FDA Quality System Regulation proposal in the supplied sources. The sources provided cover the NIST Cybersecurity Framework, NIST Privacy Framework, and Federal Trade Commission privacy and security guidance, but do not include the FDA proposal text, Federal Register notice, or authoritative FDA commentary on the rulemaking. Without access to the proposed regulatory language, effective date, scope, or specific requirements, I cannot accurately describe what the rule would require, which device classes it would affect, or what compliance timelines manufacturers would face.

What This Means in Practice

Based on the general regulatory structure of FDA quality systems and design control requirements under 21 CFR Part 820, any cybersecurity amendments would likely require manufacturers to establish documented processes in several areas. These would typically include threat modeling during the design phase, formal cybersecurity risk assessment as part of design verification and validation, secure configuration management, and defined procedures for post-market vulnerability management and coordinated disclosure.

The critical shift would be from treating cybersecurity as a technical issue managed by IT or engineering teams to treating it as a quality and regulatory compliance requirement owned at the management level. Quality System Regulation obligations fall on the manufacturer's management with responsibility for design and development, which means the same executives accountable for device safety would become accountable for cybersecurity outcomes.

The Ownership Gap

Most medical device manufacturers face a structural problem: leadership is accountable for a security outcome, but no single executive clearly owns cybersecurity strategy, risk decisions, regulatory interpretation, or the coordination between quality assurance, regulatory affairs, product development, and information security functions.

Quality assurance leadership understands design controls and risk management but typically lacks cybersecurity expertise. Information security teams understand threats and controls but rarely have authority over product design decisions or regulatory submissions. Regulatory affairs professionals manage FDA interactions but often depend on other functions to translate cybersecurity requirements into compliant processes. This fragmentation creates gaps in accountability, inconsistent risk decisions, and documentation that may not satisfy regulatory expectations.

What Adequate Ownership Looks Like

Adequate cybersecurity governance in a regulated device manufacturer requires executive-level ownership with cross-functional authority. This role translates regulatory requirements into actionable design controls, makes risk acceptance decisions within the organization's risk tolerance, defines the cybersecurity risk management framework that integrates with existing quality systems, coordinates between product development and security functions, and maintains the documentation necessary to demonstrate compliance during FDA inspections.

This is the function a virtual CISO performs. [Virtual CISO leadership](/vciso/) provides the strategic ownership, regulatory judgment, and cross-functional coordination that turns a compliance obligation into a governed process with clear accountability.

Relationship to Broader Framework Readiness

FDA cybersecurity requirements do not exist in isolation. Medical device manufacturers with operations in the EU face requirements under the Medical Device Regulation (MDR) and the proposed Cyber Resilience Act. Those handling health data must consider HIPAA if they are covered entities or business associates, and increasingly face scrutiny under state privacy laws and Federal Trade Commission enforcement under Section 5 authority for unfair and deceptive practices related to data security claims.

The NIST Cybersecurity Framework provides a common language for managing cybersecurity risk across these regulatory requirements. Organizations in multiple sectors use the Framework to structure their cybersecurity programs, and it has become a de facto standard for demonstrating reasonable security practices. The Framework's Core functions—Govern, Identify, Protect, Detect, Respond, and Recover—align well with the risk management approach FDA expects in device quality systems.

A cybersecurity program designed to meet FDA Quality System Regulation requirements can often be structured to also satisfy Framework outcomes, creating a foundation that addresses multiple regulatory expectations without duplicating governance structures.

What Leadership Should Do Next

Leadership should begin by establishing clear accountability. Identify a single executive owner for cybersecurity governance across the product lifecycle—someone with authority to make risk decisions, direct resources across functions, and speak for the organization's cybersecurity posture to regulators and the board.

Second, assess the current state honestly. Map existing cybersecurity activities against quality system requirements to identify documentation gaps, unclear handoffs between functions, and risk decisions being made without appropriate authority or documentation. This assessment should answer whether the organization could demonstrate to an FDA inspector that cybersecurity risk is managed with the same rigor as other design inputs.

Third, define the integration points. Cybersecurity risk management must connect to design and development planning, design input requirements, design verification and validation, design transfer, and post-market surveillance. Each integration point needs defined responsibilities, documented procedures, and records that demonstrate the process was followed.

Fourth, establish a post-market vulnerability management process. This includes monitoring for new threats affecting deployed devices, assessing the risk of identified vulnerabilities, determining whether a response qualifies as a device modification requiring regulatory submission, and maintaining records of these decisions. This process must be documented and auditable.

If the organization lacks the internal cybersecurity expertise or executive capacity to own this function, a virtual CISO engagement can close that gap. This is not a question of additional compliance documentation—it is a question of whether cybersecurity risk is genuinely governed at the executive level or remains distributed across functions without clear accountability.

Heights Consulting Group provides virtual CISO leadership specifically structured for regulated organizations facing this accountability gap. If you are a quality assurance, regulatory affairs, or product development executive responsible for cybersecurity outcomes without clear ownership or a defined path to compliance, a confidential consultation can clarify what adequate governance looks like for your organization and whether a vCISO engagement would address the gap. This is offered once, at the point where the decision matters.